ClinicalTrials.gg
Active, not recruitingNCT04716231ORIGIN 3Updated Oct 1, 2026Results posted

Atacicept in Subjects With IgA Nephropathy

A Phase 3 interventional study of Atacicept and Placebo to match Atacicept in IgA Nephropathy and Berger Disease, sponsored by Vera Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Vera Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 1, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
12th of 69
428 · median 72
Started
2023
with 5 others
Phase 3
23 of 75
10 open now
Primary completion
2025-05
later than 1 of 38 live
Registered
32nd of 75
by date
Lead sponsor
4 of 75
Vera Therapeutics, Inc.

Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 12th largest by enrollment of the 69 interventional ones that give a count, is one of 6 that started in 2023, is one of 23 in phase 3, reaches primary completion later than 1 of the 38 other live ones, and was the 32nd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Read the detailed description

This is a multi-part study comprising of the original Phase 2b study and the addition of a separate pivotal Phase 3 study.

After the completion of the primary results for the Ph 2b dose ranging study, the pivotal study will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized.

03

Conditions studied

  • IgA Nephropathy
  • Berger Disease

Keywords

  • Berger Disease
  • Berger's Disease
  • IGA Glomerulonephritis
  • IGA Nephropathy
  • Iga Nephropathy 1
  • Immunoglobulin A Nephropathy Nephritis
  • IGA Type Nephropathy, IGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have the ability to understand and sign a written form
  • Male or female of ≥18 years of age
  • Total urine protein excretion ≥1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) ≥1.0 mg/mg based on a 24-hour urine sample during the Screening Period
  • Diagnosis of IgAN as demonstrated by renal conducted within 10 years
  • ≥ 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  • On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum labeled or tolerated dose at Screening
  • Systolic blood pressure ≤150 mmHg and diastolic blood pressure ≤90 mmHg

Key Exclusion Criteria:

  • IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura), systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis
  • Total urine protein excretion ≥ 5g per 24-hour or urine protein to creatinine ratio (UPCR) ≥ 5 mg/mg based on a 24-hour urine sample during the Screening Period
  • Evidence of rapidly progressive glomerulonephritis (loss of ≥ 50% of eGFR within 3 months of screening)
  • Evidence of nephrotic syndrome within 6 months of screening (serum albumin \<30g/L in association with UPCR >3.5 mg/mg
  • Renal or other organ transplantation prior to, or expected during the study
  • Concomitant chronic renal disease in addition to IgAN
  • Uncontrolled diabetes, defined as -A1c () >7.5% at screening
  • History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of active TB determined by a positive Quantiferon test
  • Participation in the Phase 2b (Parts A and B) study or any previous treatment with atacicept
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
428 participants (actual)

Study arms

  • Experimental
    Atacicept Dose 150mg

    Atacicept 150mg once weekly subcutaneous (SC) injections

    Biological: Atacicept

  • Placebo comparator
    Placebo to match Atacicept (Part C/D)

    Placebo to match Atacicept once weekly subcutaneous (SC) injection

    Other: Placebo to match Atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)

    Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period.

    Time frame: 36 Weeks

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneAtacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)
Started214214
Completed00
Not completed214214

Outcome measures

PrimaryPercentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)

Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period.

Time frame:
36 Weeks
Reported as:
Mean · mean UPCR percent Change at Week 36
Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)
mean UPCR percent Change at Week 36Atacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)
Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)-46 (-53 to -38)-7 (-19 to 8)

Adverse events

Collected over Data entered is representative of the 36 week interim analysis and will be updated with the final analysis at 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atacicept Dose 150mg0/214 (0%)1/214 (0.5%)81/214 (37.9%)
Placebo to Match Atacicept (Part C/D)0/214 (0%)11/214 (5.1%)34/214 (15.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventAtacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)
GastroenteritisInfections and infestations0/2141/214
Lower respiratory tract infectionInfections and infestations0/2141/214
PneumoniaInfections and infestations0/2141/214
PyelonephritisInfections and infestations0/2141/214
CholecystitisHepatobiliary disorders1/2140/214
Cholecystitis acuteHepatobiliary disorders0/2141/214
IgA nephropathyRenal and urinary disorders0/2141/214
Renal impairmentRenal and urinary disorders0/2141/214
Acute myocardial infarctionCardiac disorders0/2141/214
HyponatraemiaMetabolism and nutrition disorders0/2141/214
Most frequent other events
Most frequent other events
EventAtacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)
Injection site reactionSkin and subcutaneous tissue disorders41/2144/214
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders26/21419/214
NasopharyngitisInfections and infestations17/21413/214
Injection site erythemaSkin and subcutaneous tissue disorders12/2141/214

Baseline characteristics

Age, Customized
Age, Customized(Participants)Atacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)Total
<45129132261
>=45-<658076156
>=655611
Sex: Female, Male
Sex: Female, Male(Participants)Atacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)Total
Female9282174
Male122132254
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Atacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)Total
Hispanic or Latino271542
Not Hispanic or Latino187199386
Region of Enrollment
Region of Enrollment(Participants)Atacicept Dose 150mgPlacebo to Match Atacicept (Part C/D)Total
India293160
United States222042
Japan181634
South Korea161531
Turkey (Türkiye)151530
Philippines101020
Brazil9918
China7916
Poland61016
Malaysia8715
United Kingdom8614
Argentina10313
Denmark5712
Ireland6612
Sri Lanka7512
Thailand2810
Australia628
Belgium358
Taiwan448
Canada527
Czechia347
Germany437
Greece167
Spain347
Croatia235
Hong Kong112
Portugal112
Singapore202
Estonia011
France011
Italy101
08

Study locations

1 site
  • ORIGIN 3 Global Site Contact Information
    Brisbane, California 94005, United States
09

References and documents

Publications

  • Barratt J, Chen K, Lafayette R. A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy. Curr Med Res Opin. 2025 Dec;41(12):2287-2301. doi: 10.1080/03007995.2026.2615321. Epub 2026 Feb 1. PubMed 41620980 ↗
  • Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesar V, Trimarchi H, Wei X, Zhang H, Barratt J; ORIGIN Phase 3 Trial Investigators. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N Engl J Med. 2026 Feb 12;394(7):647-657. doi: 10.1056/NEJMoa2510198. Epub 2025 Nov 6. PubMed 41196369 ↗
  • Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RKS, Singh H, Tesar V, Lafayette R; ORIGIN Phase 2b Investigators. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J Am Soc Nephrol. 2025 Apr 1;36(4):679-687. doi: 10.1681/ASN.0000000541. Epub 2024 Oct 26. PubMed 39462308 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in May 2025, 22 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 20, 2021
StartActual
Jun 29, 2023
Primary completionActual
May 15, 2025
CompletionEst.
Jul 2028
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Enrollment
376 (estimated)→428 (actual)
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage Change from baselineFrom Baseline in urine proteinUrine Protein to creatinine ratioCreatinine Ratio (UPCR)Time frame: 36 Weeks
Oct 1, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedAnnualized rate of change in estimated glomerular filtration rate (eGFR)Time frame: 52 and 104 Weeks
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Enrollment 376 (estimated)→428 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage Change from baselineFrom Baseline in urine proteinUrine Protein to creatinine ratioCreatinine Ratio (UPCR)Time frame: 36 Weeks
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedAnnualized rate of change in estimated glomerular filtration rate (eGFR)Time frame: 52 and 104 Weeks
    + 4 other changes: verification date, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04716231
Lead sponsor
Vera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2021
Start date
Jun 29, 2023
Primary completion
May 15, 2025
Completion
Jul 2028 (estimated)
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Eric Michael, MD
study director · Senior Director, Clinical Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion